Physician profile
Shab E Gul Rahim
NPI 1417473968
$2,455.84
in general payments reported to CMS, 2019-2025
28 companies · $899 in 2025
The $899 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $128 · 2021: $13.72 · 2023: $98.01 · 2024: $1,109 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.15 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $190.58 | 2024-2025 | Velphoro, Velphoro |
| Janssen Pharmaceuticals, INC | $177.63 | 2019-2020 | |
| Amgen INC. | $167.28 | 2024-2025 | Tavneos, Uplizna |
| Mallinckrodt Hospital Products INC. | $126.55 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $120.82 | 2023-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $117.75 | 2024-2025 | |
| Kyowa Kirin, INC. | $116.55 | 2024-2025 | Crysvita |
| Glaxosmithkline, LLC. | $109.67 | 2024-2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $108.60 | 2024-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.60 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $104.61 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $103.74 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $97.31 | 2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $87.57 | 2023-2024 | Auryxia, Vafseo |
| Allergan, INC. | $83.22 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $80.85 | 2024-2025 | Filspari |
| Shield Therapeutics INC | $72.51 | 2024 | |
| Apellis Pharmaceuticals, INC. | $67.86 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $61.09 | 2024 | |
| Insmed, INC. | $55.64 | 2019-2021 | |
| Genzyme Corporation | $55.47 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $54.68 | 2024-2025 | Lupkynis |
| Novo Nordisk INC | $54.67 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $48.21 | 2024 | Keveyis |
| Mozarc Medical US LLC | $34.69 | 2025 | Argyle |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.99 | 2019 | |
| Calliditas Therapeutics US INC. | $17.15 | 2025 | Tarpeyo |
| Pfizer INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shab E Gul Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.